The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
Primary immune thrombocytopenia is an autoimmune disorder characterised by decreased platelet counts and increased bleeding risk. Corticosteroids have been the standard initial treatment of primary immune thrombocytopenia for more than 30 years. The aim of this randomized controlled trial is to compare the efficacy and safety of high-dose dexamethasone in treating new-diagnosed primary immune thrombocytopenia (ITP) in di-cycle and tri-cycle.